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The interaction of IL-2 with specific cellular receptors plays a key role in
antigen-stimulated proliferation ofT cells. IL-2 is secreted by activated T cells
and can bind to low- and high-affinity receptors concomitantly expressed (Kd
generally reported as 1-30 nM and 5-90 pM, respectively ; for example see
reference 1) . High- but not low-affinity receptors mediate internalization of IL-
2(2) .
Until recently (3-6) the biochemical features distinguishing these two classes
of receptors were unknown, although on human cells, both classes were known
to share the epitope of monoclonal anti-Tac antibody (7) . Tac antigen is a 55-
kD glycoprotein (p55) capable of binding IL-2 (7, 8) . Crosslinking ['251]IL-2 to
activatedT cells provided indirect data for a 70-77-kD membrane protein (p70,
IL-2-R-,6), which upon associating with p55 (IL-2-R-a, Tac antigen) transforms
it into a high-affinity site (3). A broad band at 68-72 kD represents IL-2 cross-
linked to p55 (reference 3 and Fig. 1 A, lane a) . An 85-92-kD doublet (reference
3 and Fig. I A, lane a) was immunoprecipitated with anti-IL-2 mAb 17A1 (Fig .
1 A, lane b) but not with anti-p55 antisera (3) . This doublet was hypothesized to
represent IL-2 complexed to a protein of 70-75 kD (3-6), which appeared
capable of binding IL-2 directly (4-6).
We now report the direct identification of IL-2-R-# (p70) as a 65-77-kD
glycoprotein, distinct from p55 . We detail a purification scheme for the IL-2/
p70 complex and study expression ofp70 on subsets of PBMC .
Materials and Methods
Cell Preparation and Cell Culture.
￿
HUT-102112, an HTLV-I-transformed human T
cell line, was grown as described (3) . YT, a human NK-like cell line (9), was grown in
Iscove's modified Dulbecco's medium supplemented with 10% calf serum, 100 U/ml
penicillin, 100 Ag/ml streptomycin, and 3 g/liter sodium bicarbonate .
Human PBMC were isolated on Ficoll-Hypaque (LSM ; Litton Bionetics, Kensington,
MD) gradients . CD4+ and CD8+ T cells (98-99% pure) were prepared by depletion of
plastic and nylon wool adherent PBMCs and subsequent flow cytometric sorting . B cells
were purified by rosetting monocyte-depleted PBMC (<1% nonspecific esterase-positive
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cells) with 2-amino-ethylisothiouronium bromide-treated SRBC, and removing the ro-
sette-focusing cells . Such cells were 80% surface Ig', latex noningesting cells. Cells were
cross-linked before or after 48 h of culture in the presence of 1 :10,000 Staphylococcus
aureus Cowan I (SAC ; Calbiochem-Behring Corp ., San Diego, CA) . Monocytes were
prepared by elutriation ofPBMC and were 95% pure by Giemsa stain and flow cytometry .
Cells were crosslinked before or after 48 h of culture in the presence of 10 Fcg/ml LPS
(Sigma Chemical Co., St. Louis, MO) and 50 U/ml of IFN-y (Biogen, Cambridge, MA) .
Crosslinking '257-labeled IL-2 to Cells.
￿
["'I]IL-2 (New England Nuclear, Boston, MA)
was bound to cells, crosslinked with disuccinimidyl suberate (DSS ; Pierce Chemical Co .,
Rockford, IL), and lysed in extraction buffer (3) before electrophoresis or immunopre-
cipitation .
Direct Identification ofp70.
￿
HUT-102112 cells were labeled overnight with 125 uCi/ml
['H]mannose (ICN K & K Laboratories Inc ., Plainview, NY) in RPMI 1640 medium
containing 10% dialyzed FCS, 200 mg/liter glucose, and 30 mg/liter L-glutamine . 2 X
108 cells were washed and resuspended in binding buffer (3), tumbled with 400 pM IL-2
for 1 h at 4°C, pelleted at 400 g, resuspended at 2.5 X 106 cells/ml of PBS, 1 MM MgC12 ,
pH 8.3, and crosslinked with dithiobissuccinimidyl propionate (DSP ; Pierce Chemical
Co.), as described for DSS (3). Cells were extracted, precipitated with 17A1 or control
RPC5 (Litton Bionetics) mAbs as described (3), boiled in SDS, and mixed with molecular
weight markers . A 7.5% two-dimensional nonreducing/reducing diagonal gel was per-
formed as described (10) .
PreparativeImmunoafnity Column .
￿
0.5-3.0 X 10'° YT cells were incubated in binding
buffer with 6 nM IL-2 for 1 h at 4°C, were resuspended in crosslinking buffer, and DSS
(20,ug/ml) was added as described (3) . Cells were extracted and extracts ofYT cells were
crosslinked with [ '25I]IL-2 added to the preparative lysate . Total lysate at 0.65% SDS was
passed over a 17A1-Sepharose 4B column. The column was washed with 40 vol of 50
mM Tris, 300mM NaCl, 0.5% NP-40, 0.65% SDS, pH 7.4 ; 20 vol of 10mM Tris, 300
mM NaCl, 0 .1 % NP-40, 0.1% SDS, pH 7.4 ; and 10 vol of 10 mM Tris, 0.1% SDS, pH
7.4 ; and eluted with 2 .5 vol of 0.1 M Tris, 500 mM NaCI, 0.1% SDS, pH 11 .4 . The
eluate was neutralized with HCI, concentrated in Centricon-30 tubes (Amicon Corp .,
Danvers, MA) and 20% analyzed by silver staining ofanSDS gel to assess yield and purity .
Results
Direct Identification ofIL-2-R-# as a65-77-kD Glycoprotein .
￿
To directly identify
the unknown species in the 85-92-kD complex, we bound 400 pM IL-2 to [sH]
mannose-labeled HUT-102112 cells, crosslinked using the cleavable crosslinker,
DSP, and we analyzed anti-IL-2 (17A1) immunoprecipitates of cellular lysates
on two-dimensional diagonal SDS gels (Fig . 1 B) . IL-2-R-0 was identified as a
65-77-kD doublet, most consistent with cleavage in the second dimension of a
single, previously crosslinked IL-2 molecule (Fig . 1 B) . This is the first demon-
stration of p70 as a distinct, uncrosslinked glycoprotein . p55 was also detected
below the diagonal . Immunoprecipitation with control RPC5 yielded no spots
below the diagonal (Fig . 1 C) .
Purification ofIL-2/pM Complexes .
￿
With direct evidence that p70 was distinct
from p55, we were interested in purifying p70 . Because of diminished ability of
solubilized p70 tobind IL-2 (unpublished observations) we isolated the IL-2/p70
complex using an anti-IL-2 immunoaffinity purification technique and YT cells,
which express high levels ofp70 (5) . By comparison to standard protein markers,
we estimate our yield to be on the order of 1 ug of the IL-2/p70 complex (^-10
pmol) per preparation (Fig . 2) . We are using this material as an immunogen and
for microsequencing .
Expression ofp70 on PBMC.
￿
Above, we studied p70 as a component of high-
affinity IL-2-Rs . Yet, data suggest p70 can bind IL-2 independently of p55 (4-SHARON ET AL .
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FIGURE 1 . (A) Crosslinking HUT-102B2
Cells to 100pM [121I]IL-2 (high-affinity condi-
tions) with DSS and analysis by SDS-PAGE .
(Lane a) Extracts of treated cells. (Lane b)
Anti-IL-2 (17A1) immunoprecipitates of
these extracts. (B andC) Two-dimensional di-
agonal gel analysis of IL-2-R chains . HUT-
102B2 cells were labeled with ['H]mannose,
bound to 400 pM IL-2, and cross-linked with
the cleavable crosslinker, DSP . Extracts were
immunoprecipitated with 17A1 (B) or a con-
trol antibody, RPC5 (C), and subjected to elec-
trophoresis on atwo-dimensional nonreducing
(NR)/reducing (R) gel system .
FIGURE 2 .
￿
Immunoaffinity-purified IL-2/p70 complex . 2 x 10'° YT cells
were bound to 6 nM IL-2, crosslinked with DSS, extracted, and lysate was
passed over a 17A1 column . An aliquot of thecolumn eluate was analyzed by
silver stain of an SDS %i . Thearrow denotes a silver-impregnated band that
comigrates with the [ s5I]IL-2/p70 band that was copurified on the same
17A1 column .1268
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FIGURE 3 .
￿
PBMCswere cross-linked using
1 nM [' 2511IL-2 and DSS . Lysates from 10
x 10 6 cells were subjected to electrophoresis
in each lane . PBMC andCD4' and CD8'T
cell subsets were crosslinked immediately
after preparation . B cells and monocytes
were crosslinked before or after 48 h of
culture with SAC or LPS and IFN-y . The
additional bands in the T cell lanes repre-
sent high molecular mass material not en-
tering the gel, free IL-2 at the dye front,
anda band of
￿
35,000, which is seen with
variable intensity .
6) . Further, high-dose IL-2 can induce proliferation (11) and cytolytic activity
(12, 13) on Tac-negative PBMC . We therefore evaluated subpopulations of
human PBMC for the presence of p70 (Fig . 3) . [1251]IL-2 was crosslinked to
PBMC, and cell extracts were analyzed by SDS-PAGE . p70 was indeed present
on circulatingPBMC . Densitometric analysis of several similar gels with samples
derived from multiple donors indicated an upper/lower complex ratio of>10:1 .
Both CD4' and CD8+ subpopulations of resting T cells expressed p70 and p55
in similar fashion to PBMCs . Thus, p70 can exist unassociated with p55 on these
cells and can directly bind IL-2 . Crosslinking to unstimulated B cells and
monocytes showed little if any p70 or p55. Stimulation of B cells with SAC or
monocytes with LPS induced expression of both p70 and p55 . This effect of
LPS was enhanced by IFN-7.
Discussion
When IL-2 binds to activated T cells under high-affinity conditions it can be
crosslinked into either 68-72-kD or 85-92-kD complexes . Although the 68-72-
kD band was established as a dimer of IL-2 and p55 (3), only indirect evidence
suggested the identity of the unknown component(s) in the 85-92-kD complex
(3-6) . We have now directly identified the IL-2-R a chain as a 65-77-kD
glycoprotein (p70) by analysis on a two-dimensional diagonal gel, clearly estab-
lishing the existence ofp70 .
Immunoaffinity techniques have allowed us to partially purify IL-2/p70 cross-
linked complexes, which have at least a doublet appearance on SDS-PAGE (Fig .
I A) . That isolated, uncrosslinked p70 (Fig . 1 B) also has a doublet character
suggests heterogeneity, which we hypothesize is due at least in part to variable
posttranslational modifications . Another (we believe less likely) possibility is that
the doublet represents two distinct glycoproteins . When analyzed by a two-
dimensional O'Farrell gel, the Immunoaffinity-purified complex migrated within
a limited pI range (5.3-5.9) in a way consistent with variable sialylation playing
a part in the heterogeneity detected (unpublished observations) .SHARON ET AL.
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Activated lymphocytes express ^-10-fold more low-affinity Tac antigen (p55)
sites than high-affinity sites (p55/p70-associated chains; reference 1). It is un-
clear, however, whether p70 can exist unassociated with p55 on the surface of
such lymphoblasts. Crosslinking with 1251-IL-2, binding studies, flow cytometry
with anti-Tac, and Northern blots with p55 cDNAs together suggest a good
correlation between intensity ofcrosslinked bands and cell surface expression of
p55 and p70 on both normal and leukemic Tcells. On the basis of cross-linking,
we now report that human PBMC express more p70 than p55 (see also reference
6). Wealso demonstratethat both the CD4'' and CD8+ subpopulationsofTcells,
but not B cells or monocytes, express p70 in the unstimulated state. However,
activated B cells and monocytes express both p70 and p55, consistent with
reports ofhigh-affinity IL-2-Rs on such cells (14, 15).
rIL-2 alone can induce PBMC to proliferate (11) to evolve lymphokine-
activated killer activity (12) and to augment the activity of NK cells (13). p70
plays arole in these responsesand is the principal IL-2 bindingprotein expressed
on large granular lymphocytes (16). In comparison with T cells, large granular
lymphocytes express more p70 and are more responsive to IL-2 (16).
Although we have identified p55 and p70 as components of high-affinity IL-
2-Rs, it is important to recognize the possibility that there may exist other
subunits that are not cross-linked to IL-2. In this regard, bands of 113 and 180
kD have been observed in anti-Tac immunoprecipitations of lymphoblasts (7, 8)
and studies of the murine IL-2-R provide data consistent with the possibility of
a 100-kD protein as a component of the high-affinity receptor (17). We hope
that the methodology described herein will facilitate development ofantibodies
to better define the biochemistry ofp70 and its role in the immune response.
Summary
IL-2 binds to high- and low-affinity receptors on activated T cells. The high-
affinity receptor was hypothesized to consist of the noncovalent association
between the a chain (IL-2-R-a, p55) and a ,# chain (IL-2-R-0, p70), whereas the
low-affinity receptor consists of p55 without p70. We now directly identify p70
as a 65-77-kD glycoprotein doublet. Preparative quantities of the IL-2/p70
complex have been isolated. Further, we demonstrate that p70 is the principal
IL-2 binding protein on both resting CD4' and CD8+ Tcells and that both p70
and p55 can be induced on normal B cells and monocytes.
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